Safety, Tolerability, and Pharmacokinetics of IMU‐935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double‐Blind, Placebo‐Controlled, First‐in‐Human Phase 1 Study
Polasek, Thomas M., Leelasena, Indika, Betscheider, Irina, Marolt, Marija, Kohlhof, Hella, Vitt, Daniel, Fliegert, Frank, Muehler, Andreas R.
Published in Clinical pharmacology in drug development (01.05.2023)
Published in Clinical pharmacology in drug development (01.05.2023)
Get full text
Journal Article